Prevalence of eyes with specific optical coherence tomography (OCT)-based biomarkers and Gass lesion types stratified by best-corrected visual acuity better or worse than 0.4 LogMAR
| BCVA <0.4 LogMAR (≥20/50) | BCVA ≥0.4 LogMAR (<20/50) | P value | |
| Number of eyes | 60 | 35 | – |
| Age (Years) (mean, median, range) | 37.5, 34, 4 to 87 | 41.2, 45, 7 to 84 | 0.21 |
| CST (µm) (mean, median, range) | 335.7, 334, 210 to 570 | 331.3, 300, 73 to 627 | 0.15 |
| Pre-VL (%) | 28.3 | 2.9 | 0.02* |
| Solid VL (%) | 13.3 | 2.9 | 0.2 |
| SRF (%) | 61.7 | 68.6 | 0.29 |
| Pillar (%) | 20 | 31.4 | 0.18 |
| FCE (%) | 15 | 28.6 | 0.14 |
| IRF (%) | 6.7 | 28.6 | 0.04* |
| Fibrosis and/or atrophy (%) | 1.7 | 17.1 | 0.21 |
| CNV (%) | 6.7 | 17.1 | 0.2 |
| Gass lesion type (%) | |||
| 1 | 30 | 2.8 | 0.02* |
| 2 | 26.7 | 17.1 | 0.44 |
| 3 | 21.7 | 22.9 | 0.93 |
| 4 | 16.6 | 22.9 | 0.62 |
| 5 | 5 | 34.3 | 0.02* |
*P value <0.05 (Mann-Whitney U test) considered statistically significant.
BCVA, best-corrected visual acuity; CNV, choroidal neovascularisation; CST, central subfield thickness; FCE, focal choroidal excavation; IRF, intraretinal fluid; SRF, subretinal fluid; VL, vitelliform.